A Trial of HRS-6768 in Patients With Advanced Solid Tumors
NCT06925581 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 84
Last updated 2025-12-03
Summary
The study is being conducted to evaluate the pharmacokinetics, radiation dosimetry, safety and preliminary efficacy of HRS-6768. To explore the reasonable dosage of HRS-6768 in the treatment of patients with advanced solid tumors.
Conditions
Interventions
- DRUG
-
HRS-6768
HRS-6768
Sponsors & Collaborators
-
Jiangsu HengRui Medicine Co., Ltd.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-04-24
- Primary Completion
- 2026-04-30
- Completion
- 2027-04-30
Countries
- China
Study Locations
More Related Trials
-
A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
NCT06057610 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients
NCT06555068 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.
NCT06015048 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast Cancer
NCT05044988 ·Status: UNKNOWN ·Phase: PHASE2
-
BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
NCT06253195 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer
NCT06167694 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer
NCT04993430 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors
NCT04446260 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma
NCT05318339 ·Status: UNKNOWN ·Phase: PHASE2
-
A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer
NCT07196774 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
NCT06198751 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
NCT05150691 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping
NCT06561022 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
NCT04631835 ·Status: UNKNOWN ·Phase: PHASE1
-
Clinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast Cancer
NCT07305246 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Reverse HER2-negative Immune Resistant Breast Cancer
NCT06731140 ·Status: RECRUITING ·Phase: PHASE2
-
A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer
NCT06974929 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer Patients
NCT06788197 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
NCT06431490 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
NCT06726148 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer
NCT06413745 ·Status: RECRUITING ·Phase: PHASE2
-
SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial
NCT05814354 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC
NCT04398108 ·Status: COMPLETED ·Phase: PHASE1
-
HB1801 Combined Treatment of HER2-positive Breast Cancer
NCT07116824 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
NCT06927180 ·Status: RECRUITING ·Phase: PHASE2